Korean Market
MATR
AprilBio
★

AprilBio Decides 141.8 Billion Won Third-Party Allotment for R&D Funding, Dilution of 17.5% and Change in Control

 
EXCH
AprilBio
★

AprilBio Receives Inquiry Disclosure Request Regarding Acquisition Rumor by TK Chemical, Increasing Stock Volatility and M&A Expectations

 
OWNR
AprilBio
★

SM Sino Technology Investment reduces AprilBio stake from 6.99% to 5.41% through open market sales, maintaining simple investment purpose

 
OWNR
AprilBio
★

AprilBio Advisor Seo Sang-jun Exercises Stock Options to Acquire 20,000 Shares, Minimal Dilution Impact

 
OWNR
AprilBio
★

AprilBio Non-Registered Director Heo Byeong-ung Acquires 17,500 Shares via Stock Option Exercise, Minimal Dilution Impact

 
OWNR
AprilBio
★

Non-Executive Director Jin Hong-guk Exercises 20,000 Stock Options in AprilBio, Stake Rises to 0.13%, Limited Impact on Share Price

 
PERI
AprilBio
★★

AprilBio 2026 Q1: Evommune Milestone Revenue and 95 Billion KRW Cash Holdings

 
EXCH
AprilBio
★

Early termination of SAFA fusion protein contract with Yuhan, strategic shift